STOCK TITAN

Ocugen Inc - OCGN STOCK NEWS

Welcome to our dedicated page for Ocugen news (Ticker: OCGN), a resource for investors and traders seeking the latest updates and insights on Ocugen stock.

Ocugen Inc. (OCGN) is a clinical-stage biopharmaceutical company pioneering gene therapies for retinal diseases and innovative vaccine platforms. This dedicated news hub provides investors and researchers with timely updates on Ocugen’s scientific advancements, regulatory milestones, and strategic initiatives.

Access verified press releases and curated financial news covering clinical trial developments, partnership announcements, and corporate updates. Our repository includes updates on modifier gene therapy programs for conditions like retinitis pigmentosa, inhaled vaccine research, and ocular disorder treatments undergoing regulatory review.

Key content categories include progress reports on Phase I-III trials, FDA designations, intellectual property updates, and financial performance summaries. Bookmark this page for streamlined tracking of OCGN’s advancements in gene editing technologies and mucosal vaccine development.

Rhea-AI Summary
Ocugen's Chief Scientific Officer, Arun Upadhyay, will be speaking at the 4th Annual Gene Therapy for Ophthalmic Disorders conference in Boston. He will discuss endpoints for gene therapy clinical trials and the design of first-in-human clinical studies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.23%
Tags
conferences
-
Rhea-AI Summary
Ocugen to participate in fireside chat at Chardan 7th Annual Genetic Medicines Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.49%
Tags
conferences
-
Rhea-AI Summary
Connie Collingsworth, former COO of the Bill and Melinda Gates Foundation, joins Ocugen's Business Advisory Board (BAB) to drive partnerships and access to therapies worldwide. Her financial background will support new business development opportunities. Collingsworth's expertise and global connections may strengthen Ocugen's position in the market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.01%
Tags
management
Rhea-AI Summary
Ocugen CEO to participate in Cantor Fitzgerald Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.49%
Tags
conferences
-
Rhea-AI Summary
Positive safety and efficacy trends observed in the clinical study update for OCU400 investigational drug product in RP and LCA subjects. 83% of subjects demonstrated stabilization or improvement in treated eye either on BCVA or LLVA or MLMT scores from baseline. Notably, 86% of RHO mutation subjects experienced either stabilization of or increase in MLMT scores from baseline including a subset of 29% that demonstrated a 3 Lux luminance level improvement. OCU400 has the potential to be a gene-agnostic therapeutic for RP and LCA patients with inherited retinal degeneration. No serious adverse events were reported in the low and medium-dose cohorts.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.29%
Tags
-
Rhea-AI Summary
Ocugen to share updated results from Phase 1/2 trial of OCU400 for Retinitis Pigmentosa and Leber Congenital Amaurosis. Investor and Analyst Event on Sept 13. Webcast and conference call details provided.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.29%
Tags
conferences
Rhea-AI Summary
Ocugen reports Q2 2023 financial results and provides business update, plans to initiate Phase 1/2 trials for OCU410 and OCU410ST gene therapies by end of 2023, plans to share updated data on OCU400 this quarter, and continues discussions for government support of its inhaled vaccines.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.03%
Tags
-
Rhea-AI Summary
Ocugen to host conference call and webcast to discuss Q2 2023 financial results and business update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.23%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.63%
Tags
conferences
Rhea-AI Summary
Ocugen's 2023 Annual Meeting of Shareholders adjourned due to lack of required quorum. The meeting will resume on June 23, 2023, virtually. Shareholders who have already submitted a proxy do not need to vote again.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.22%
Tags
none
Ocugen Inc

Nasdaq:OCGN

OCGN Rankings

OCGN Stock Data

198.39M
288.29M
1.27%
24.84%
21.81%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
MALVERN